Tactile Systems downgraded by B. Riley Securities with a new price target
$TCMD
Medical/Dental Instruments
Health Care
B. Riley Securities downgraded Tactile Systems from Buy to Neutral and set a new price target of $18.00 from $23.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $35.00 | Neutral → Overweight | Piper Sandler |
| 11/4/2025 | $28.00 | Neutral → Buy | BTIG Research |
| 10/3/2025 | $23.50 | Buy | Lake Street |
| 5/6/2025 | $14.00 | Overweight → Neutral | Piper Sandler |
| 2/19/2025 | $23.00 → $18.00 | Buy → Neutral | B. Riley Securities |
| 11/5/2024 | Outperform → Perform | Oppenheimer | |
| 11/5/2024 | Buy → Neutral | BTIG Research | |
| 9/26/2024 | $23.00 | Buy | B. Riley Securities |
PRE 14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
144 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
3 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM
MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Andrea Pearson to the Company's Board of Directors ("Board") and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, market
Piper Sandler upgraded Tactile Systems from Neutral to Overweight and set a new price target of $35.00
BTIG Research upgraded Tactile Systems from Neutral to Buy and set a new price target of $28.00
Lake Street initiated coverage of Tactile Systems with a rating of Buy and set a new price target of $23.50
MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Andrea Pearson to the Company's Board of Directors ("Board") and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, market
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE
MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 millionGross margin of 78% versus 75% in Q4 2024Net income of $10.6 million versus $9.7 million in Q4 2024Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 millionGross margin of 76%, compared to 74% in 2024Oper
MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that it has acquired LymphaTech Inc., for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones. Founded in 2014, LymphaTech, Inc. is a privately held medical technology company pioneering a digital, three-dimensional ("3D") full body measurement and monitoring platform designed specifically for lymphedema. Damage to the lymphatic system from chronic fluid accumulat
MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2025 financial results will be released after the market closes on Tuesday, February 17, 2026. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 17, 2026, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13758303. A live webcast of the call
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)